Advertisement

Der Nervenarzt

, Volume 74, Issue 6, pp 505–515 | Cite as

Rhabdomyolyse und Myoglobinurie

  • A. LindnerEmail author
  • S. Zierz
Übersicht

Zusammenfassung

Bei der Rhabdomyolyse kommt es zu einer Freisetzung von Muskelzellbestandteilen in den Blutkreislauf nach direkter Schädigung des Sarkolemms bzw. Ausfall der Energieversorgung innerhalb der Muskelzelle mit Anstieg potenziell toxischer Muskelzellbestandteile, Kreatinkinase (CK) und Myoglobin im Serum. Das häufige Auftreten einer assoziierten Myoglobinurie führte dazu, dass die Begriffe Rhabdomyolyse und Myoglobinurie oft synonym verwandt wurden. Komplikationen der Rhabdomyolyse sind akutes Nierenversagen, Hyperkaliämie mit Herzstillstand, disseminierte intravasale Gerinnungsstörung oder lokal ein akutes Kompartmentsyndrom. Das Krankheitsbild ist hinsichtlich der Ätiologie sehr heterogen und kann durch eine Vielzahl unterschiedlicher Erkrankungen, die zu einer Schädigung der Muskelzellmembranen, Ionenkanäle oder der muskulären Einergieversorgung führen, hervorgerufen werden.

Schlüsselwörter

Rhabdomyolyse Myoglobinurie Komplikationen Ätiologie 

Summary

Rhabdomyolysis is a disorder characterized by acute damage of the sarcolemma of the skeletal muscle leading to release of potentially toxic muscle cell components into the circulation, most notably creatine phosphokinase (CK) and myoglobin, and is frequently accompanied by myoglobinuria. Therefore, the term myoglobinuria is often used interchangeably with the term rhabdomyolysis. This disorder may result in potential life-threatening complications such as acute myoglobinuric renal failure, hyperkalemia and cardiac arrest, disseminated intravascular coagulation, and compartment syndrome. The condition is etiologically heterogeneous and may result from a large variety of diseases affecting muscle membranes, membrane ion channels, and muscle energy supply including acquired causes (e.g., exertion, crush injury and trauma, alcoholism, drugs, and toxins) and hereditary causes (e.g., disorders of carbohydrate metabolism, disorders of lipid metabolism, or diseases of the muscle associated with malignant hyperthermia). In many patients with idiopathic recurrent rhabdomyolysis, specific inherited metabolic defects have not been recognized up to now.

Keywords

Rhabdomyolysis Myoglobinuria Complications Etiology 

Literatur

  1. 1.
    Abe K, Mezaki T, Hirono N, Udaka F, Kameyama M (1990) A case of anorexia nervosa with acute renal failure resulting from rhabdomyolysis. Acta Neurol Scand 81(1):82–3Google Scholar
  2. 2.
    Adnet P, Lestavel P, Krivosic-Horber R (2000) Neuroleptic malignant syndrome. Br J Anaesth 85(1):129–35Google Scholar
  3. 3.
    Andreu AL, Bruno C, Dunne TC et al. (1999) A nonsense mutation (G15059A) in the cytochrome b gene in a patient with exercise intolerance and myoglobinuria. Ann Neurol 45(1):127–30Google Scholar
  4. 4.
    Better OS, Stein JH (1990) Early management of shock and prophylaxis of acute renal failure in traumatic rhabdomyolysis. N Engl J Med 322:825–829Google Scholar
  5. 5.
    Bierbach H, Bohl J, Goldner HJ, Majdandzic J (1983) Hypokalemic rhabdomyolysis associated with Bartter's syndrome. Klin Wochenschr 61(4):183–6Google Scholar
  6. 6.
    Billis AG, Kastanakis S, Giamarellou H, Daikos GK (1971) Acute renal failure after a meal of quail. Lancet 25:702Google Scholar
  7. 7.
    Bodner RA, Lynch T, Lewis L, Kahn D (1995) Serotonin syndrome. Neurology 45(2):219–23Google Scholar
  8. 8.
    Bloom AI, Zamir G, Muggia M, Friedlaender M, Gimmon Z, Rivkind A (1995) Torture rhabdomyorhexis—a pseudo-crush syndrome. J Trauma 38(2):252–4Google Scholar
  9. 9.
    Bouchama A, Knochel JP (2002) Heat stroke. N Engl J Med 346(25):1978–88Google Scholar
  10. 10.
    Braakhekke JP, de Bruin MI, Stegeman DF, Wevers RA, Binkhorst RA, Joosten EM (1986) The second wind phenomenon in McArdle's disease. Brain 109:1087–101Google Scholar
  11. 11.
    Brumback RA, Feeback DL, Leech RW (1992) Rhabdomyolysis in childhood. A primer on normal muscle function and selected metabolic myopathies characterized by disordered energy production. Pediatr Clin North Am 39(4):821–58Google Scholar
  12. 12.
    Buchholz U, Mouzin E, Dickey R, Moolenaar R, Sass N, Mascola L (2000) Haff disease: from the Baltic Sea to the U.S. shore. Emerg Infect Dis 6(2):192–5Google Scholar
  13. 13.
    Buckingham BA, Roe TF, Yoon JW (1981) Rhabdomyolysis in diabetic ketoacidosis. Am J Dis Child 135(4):352–4Google Scholar
  14. 14.
    Buckley PF, Hutchinson M (1995) Neuroleptic malignant syndrome. J Neurol Neurosurg Psychiatry 58(3):271–3Google Scholar
  15. 15.
    Campion DS, Arias JM, Carter NW (1972) Rhabdomyolysis and myoglobinuria. Association with hypokalemia of renal tubular acidosis. JAMA 220(7):967–9Google Scholar
  16. 16.
    Caroff SN, Mann SC, Lazarus A (1987) Neuroleptic malignant syndrome. Arch Gen Psychiatry 44(9):838–40Google Scholar
  17. 17.
    Caroff SN, Mann SC (1988) Neuroleptic malignant syndrome. Psychopharmacol Bull 24(1):25–9Google Scholar
  18. 18.
    Carrier HN, Berthillier G (1980) Carnitine levels in normal children and adults and in patients with diseases muscle. Muscle Nerve 3(4):326–34Google Scholar
  19. 19.
    Chaikin H (1980) Rhabdomyolysis secondary to drug overdose and prolonged coma. South Med J 73(8):990–4Google Scholar
  20. 20.
    Chan BS, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG (1998) Serotonin syndrome resulting from drug interactions. Med J Aust 16;169(10):523–5Google Scholar
  21. 21.
    Chinnery PF, Johnson MA, Taylor RW, Lightowlers RN, Turnbull DM (1997) A novel mitochondrial tRNA phenylalanine mutation presenting with acute rhabdomyolysis. Ann Neurol 41(3):408–10Google Scholar
  22. 22.
    Christensen TE, Saxtrup O, Hansen TI et al. (1983) Familial myoglobinuria. A study of muscle and kidney pathophysiology in three brothers. Dan Med Bull 30(2):112–5Google Scholar
  23. 23.
    David WS (2000) Myoglobinuria. Neurol Clin 18(1):215–43Google Scholar
  24. 24.
    Deighan CJ, Wong KM, McLaughlin KJ, Harden P (2000) Rhabdomyolysis and acute renal failure resulting from alcohol and drug abuse. QJM 93(1):29–33Google Scholar
  25. 25.
    Deschauer M, Wieser T, Schroder R, Zierz S (2002) A novel nonsense mutation (515del4) in muscle carnitine palmitoyltransferase II deficiency. Mol Genet Metab 75(2):181–5Google Scholar
  26. 26.
    DiDonato S (1994) Disorders of lipid metabolism affecting skeletal muscle: carnitine deficiency syndrome, defects in catabolic pathway, and chanartin disease. In: Engel AG, Franzini-Armstrong C (eds) Myology. 2nd ed. McGraw-Hill, New York, pp 1587–1609Google Scholar
  27. 27.
    DiMauro S, Tsujino S (1994) Nonlysosomal glycogenoses. In: Engel AG, Franzini-Armstrong C (eds) Myology, Vol 2. Mc-Graw-Hill, New York, pp 1554–1576Google Scholar
  28. 28.
    Engel AG, Potter CS, Rosevaer JW (1964) Nucleotides and adenosine monophosphate activity of muscle in primary hypokalemic periodic paralysis. Nature 202:670–672Google Scholar
  29. 29.
    Engel, AG, Rebouche CJ (1982) Pathogenetic mechanisms in human carnitine deficiency syndromes. In: DL Schotland (ed) Disorders of the Motor Unit. Wiley, New York, pp 643–656Google Scholar
  30. 30.
    Fernandez-Sola J, Sacanella E, Estruch R, Nicolas JM, Grau JM, Urbano-Marquez A (1995) Significance of type II fiber atrophy in chronic alcoholic myopathy. J Neurol Sci 130(1):69–76Google Scholar
  31. 31.
    Fishbein WN (1985) Myoadenylate deaminase deficiency: inherited and acquired forms. Biochem Med 33(2):158–69Google Scholar
  32. 32.
    Gabow PA, Kaehny WD, Kelleher SP (1982) The spectrum of rhabdomyolysis. Medicine (Baltimore) 61(3):141–52Google Scholar
  33. 33.
    Gronert GA (1994) Malignant hyperthermia. In: Engel AG, Franzini-Armstrong C (eds) Myology, 2nd edn. McGraw-Hill, New York, pp 1661–1678Google Scholar
  34. 34.
    Haller RG, Lewis SF (1991) Glucose-induced exertional fatigue in muscle phosphofructokinase deficiency. N Engl J Med 324(6):364–9Google Scholar
  35. 35.
    Halverson PB, Kozin F, Ryan LM, Sulaiman AR (1979) Rhabdomyolysis and renal failure in hypothyroidism. Ann Intern Med 91(1):57–8Google Scholar
  36. 36.
    Hara H, Wakayama Y, Kouno Y, Yamada H, Tanaka M, Ozawa T (1994) Acute peripheral neuropathy, rhabdomyolysis, and severe lactic acidosis associated with 3243 A to G mitochondrial DNA mutation. J Neurol Neurosurg Psychiatry 57(12):1545–6Google Scholar
  37. 37.
    Haslinger B, Küchle, Sitter T, Held E (2001) Alkoholabusus mit Krampfanfall als Auslöser einer Rhabdomyolyse mit akutem Nierenversagen bei McArdle-Syndrom. Dtsch Med Wochenschr 126:1265–1268Google Scholar
  38. 38.
    Hed R, Lundmark C, Fahlgren H, Orrel S (1962) Acute muscular syndrome in alcoholism. Acta Med Scan 171:585Google Scholar
  39. 39.
    Heiman-Patterson TD (1993) Neuroleptic malignant syndrome and malignant hyperthermia. Important issues for the medical consultant. Med Clin North Am 77(2):477–92Google Scholar
  40. 40.
    Hodel C (2002) Myopathy and rhabdomyolysis with lipid-lowering drugs. Toxicol Lett 10;128(1–3):159–68Google Scholar
  41. 41.
    Hogan K (1998) The anesthetic myopathies and malignant hyperthermias. Curr Opin Neurol 11(5):469–76Google Scholar
  42. 42.
    Honda N (1983) Acute renal failure and rhabdomyolysis. Kidney Int 23(6):888–98Google Scholar
  43. 43.
    Jolly BT, Talbot-Stern J (1995) Rhabdomyolysis secondary to keyboard overuse: occupational hazard of the computer age. Am J Emerg Med 13(6):644–6Google Scholar
  44. 44.
    Kar NC, Pearson CM (1981) Muscle adenylate deaminase deficiency. Report of six new cases. Arch Neurol 38(5):279–81Google Scholar
  45. 45.
    Karadimas CL, Greenstein P, Sue CM et al. (2000) Recurrent myoglobinuria due to a nonsense mutation in the COX I gene of mitochondrial DNA. Neurology 12;55(5):644–9Google Scholar
  46. 46.
    Kazemi-Esfarajani P, Skomorwska E, Dysgaard, Jensen T (2000) No need for ischemia in the forearm exercise test for McArdle`s disease. Neurology 54 [Suppl 3]: A332Google Scholar
  47. 47.
    Kazemi-Esfarjani P, Skomorowska E, Jensen TD, Haller RG, Vissing J (2002) A nonischemic forearm exercise test for McArdle disease. Ann Neurol 52(2):153–9Google Scholar
  48. 48.
    Kelemen J, Rice DR, Bradley WG, Munsat TL, DiMauro S, Hogan EL (1982) Familial myoadenylate deaminase deficiency and exertional myalgia. Neurology 32(8):857–63Google Scholar
  49. 49.
    Kelly KJ, Garland JS, Tang TT, Shug AL, Chusid MJ (1989) Fatal rhabdomyolysis following influenza infection in a girl with familial carnitine palmityl transferase deficiency. Pediatrics 84(2):312–6Google Scholar
  50. 50.
    Khan M, Farver D (2000) Recognition, assessment and management of neuroleptic malignant syndrome. S D J Med 53(9):395–400Google Scholar
  51. 51.
    King JO, Denborough MA (1973) Anesthetic-induced malignant hyperpyrexia in children. J Pediatr 83(1):37–40Google Scholar
  52. 52.
    Knochel JP (1982) Rhabdomyolysis and myoglobinuria. Annu Rev Med 33:435–43Google Scholar
  53. 53.
    Knochel JP (1990) Catastrophic medical events with exhaustive exercise: "white collar rhabdomyolysis". Kidney Int 38(4):709–19Google Scholar
  54. 54.
    Knochel JP (1993) Mechanisms of rhabdomyolysis. Curr Opin Rheumatol 5(6):725–31Google Scholar
  55. 55.
    Kornhuber J, Weller M (1994) Neuroleptic malignant syndrome. Curr Opin Neurol 7(4):353–7Google Scholar
  56. 56.
    Lambert C, Blanloeil Y, Horber RK, Berard L, Reyford H, Pinaud M (1994) Malignant hyperthermia in a patient with hypokalemic periodic paralysis. Anesth Analg 79(5):1012–1014Google Scholar
  57. 57.
    Lindner A, Hofmann E, Naumann M, Becker G, Reichmann H (1997) Clinical, morphological, biochemical, and neuroradiological features of mitochondrial encephalomyopathies. Presentation of 19 patients. Mol Cell Biochem 174(1–2):297–303Google Scholar
  58. 58.
    Lindner A, Reichert N, Eichhorn M, Zierz S (2001) Acute compartment syndrome after forearm ischemic work test in a patient with McArdle`s disease. Neurology 56:1779–1780Google Scholar
  59. 59.
    Lofberg M, Jankala H, Paetau A, Harkonen M, Somer H (1998) Metabolic causes of recurrent rhabdomyolysis. Acta Neurol Scand 98(4):268–75Google Scholar
  60. 60.
    LoCurto MJ (1997) The serotonin syndrome. Emerg Med Clin North Am 15(3):665–75Google Scholar
  61. 61.
    Martin-Du Pan RC, Morris MA, Favre H, Junod A, Pizzolato GP, Bottani A (1999) Mitochondrial anomalies in a Swiss family with autosomal dominant myoglobinuria. Am J Med Genet 14; 69(4):365–9Google Scholar
  62. 62.
    Mastaglia FL (1992) Toxic myopathies. In: Rowland LP, DiMauro S (eds) Handbook of clinical neurology. Vol. 62. Amsterdam, North Holland, pp 595–622Google Scholar
  63. 63.
    Meinck HM, Goebel HH, Rumpf KW, Kaiser H, Neumann P (1982) The forearm ischemic work test—hazardous to McArdle patients? J Neurol Neurosurg Psychiatry 45:1144–1146Google Scholar
  64. 64.
    Melberg A, Holme E, Oldfors A, Lundberg PO (1998) Rhabdomyolysis in autosomal dominant progressive external ophthalmoplegia. Neurology 50(1):299–300Google Scholar
  65. 65.
    Meyer-Betz F (1906) Beobachtungen an einem eigenartigen mit Muskellähmungen verbundenem Fall von Hämoglobinurie. Dtsch Arch Klin Med 1001:85–127Google Scholar
  66. 66.
    Miyajima H, Takahashi Y, Kaneko E (1995) Characterization of the glycolysis in lactate dehydrogenase-A deficiency. Muscle Nerve 18(8):874–8Google Scholar
  67. 67.
    Miller F, Friedman R, Tanenbaum J, Griffin A (1991) Disseminated intravascular coagulation and acute myoglobinuric renal failure: a consequence of the serotonergic syndrome. J Clin Psychopharmacol 11(4):277–9Google Scholar
  68. 68.
    Mills KC (1997) Serotonin syndrome. A clinical update. Crit Care Clin Oct;13(4):763–83Google Scholar
  69. 69.
    Monnier N, Procaccio V, Stieglitz P, Lunardi J (1997) Malignant-hyperthermia susceptibility is associated with a mutation of the alpha 1-subunit of the human dihydropyridine-sensitive-type voltage-dependent calcium-channel receptor in skeletal muscle. Am J Hum Genet 60(6):1316–25Google Scholar
  70. 70.
    Nadel SM, Jackson JW, Ploth DW (1979) Hypokalemic rhabdomyolysis and acute renal failure. Occurrence following total parenteral nutrition. JAMA 241(21):2294–6Google Scholar
  71. 71.
    Nelson TE (2002) Malignant hyperthermia: a pharmacogenetic disease of Ca++ regulating proteins. Curr Mol Med 2(4):347–69Google Scholar
  72. 72.
    Ogilvie I, Pourfarzam M, Jackson S, Stockdale C, Bartlett K, Turnbull DM (1994) Very long-chain acyl coenzyme A dehydrogenase deficiency presenting with exercise-induced myoglobinuria. Neurology 44(3):467–73Google Scholar
  73. 73.
    Ohno K, Tanaka M, Sahashi K et al. (1991) Mitochondrial DNA deletions in inherited recurrent myoglobinuria. Ann Neurol 29(4):364–9Google Scholar
  74. 74.
    Preedy VR, Adachi J, Ueno Y et al. (2001) Alcoholic skeletal muscle myopathy: definitions, features, contribution of neuropathy, impact and diagnosis. Eur J Neurol 8(6):677–87Google Scholar
  75. 75.
    Prockop LD, Engel WK, Shug AL (1983) Nearly fatal muscle carnitine deficiency with full recovery after replacement therapy. Neurology 33(12):1629–31Google Scholar
  76. 76.
    Quane KA, Healy JM, Keating KE et al. (1993) Mutations in the ryanodine receptor gene in central core disease and malignant hyperthermia. Nat Genet 5(1):51–5Google Scholar
  77. 77.
    Ramesh V, Gardner-Medwin D (1992) Familial paroxysmal rhabdomyolysis: management of two cases of the non-exertional type. Dev Med Child Neurol 34(1):73–9Google Scholar
  78. 78.
    Richards JR (2000) Rhabdomyolysis and drugs of abuse. J Emerg Med 19(1):51–6Google Scholar
  79. 79.
    Riggs J (1998) Alcohol-associated rhabdomyolysis: ethanol induction of cytochrome P450 may potentiate myotoxicity. Clin Neuropharmacol 21(6):363–4Google Scholar
  80. 80.
    Ruitenbeek W, Poels PJ, Turnbull DM, Garavaglia B, Chalmers RA, Taylor RW, Gabreels FJ (1995) Rhabdomyolysis and acute encephalopathy in late onset medium chain acyl-CoA dehydrogenase deficiency. J Neurol Neurosurg Psychiatry 58(2):209–14Google Scholar
  81. 81.
    Rumpf KW, Kaiser H, Schulze F, Koop H, Trapp VE (1981) Myoglobinuria in malabsorption after small bowel resection. Med Klin 76(20):563–4Google Scholar
  82. 82.
    Saudubray JM, Martin D, de Lonlay P et al. (1999) Recognition and management of fatty acid oxidation defects: a series of 107 patients. J Inherit Metab Dis 22(4):488–502Google Scholar
  83. 83.
    Schwengel D, Ludwig S (1985) Rhabdomyolysis and myoglobinuria as manifestations of child abuse. Pediatr Emerg Care 1(4):194–7Google Scholar
  84. 84.
    Shumate JB, Katnik R, Ruiz M, Kaiser K, Frieden C, Brooke MH, Carroll JE (1979) Myoadenylate deaminase deficiency. Muscle Nerve 2(3):213–6Google Scholar
  85. 85.
    Singh U, Scheld WM (1996) Infectious etiologies of rhabdomyolysis: three case reports and review. Clin Infect Dis. 22(4):642–9Google Scholar
  86. 86.
    Singhal PC, Abramovici M, Venkatesan J (1990) Rhabdomyolysis in the hyperosmolal state. Am J Med 88(1):9–12Google Scholar
  87. 87.
    Slater MS, Mullins RJ (1998) Rhabdomyolysis and myoglobinuric renal failure in trauma and surgical patients: a review. J Am Coll Surg 186(6):693–716Google Scholar
  88. 88.
    Steinfath M, Wappler F, Scholz J (2002) Malignant hyperthermia. General, clinical and experimental aspects. Anaesthesist (4):328–45Google Scholar
  89. 89.
    Sultana SR, Byrne DJ (1996). 'Raver's' haematuria. J R Coll Surg Edinb 41(6):419–20Google Scholar
  90. 90.
    Tein I, Di Mauro S, Rowlan LP (1992) Myoglobinuria. In: Rowland LP, DiMauro S (eds) Handbook of clinical neurology. Vol. 62. Amsterdam, North Holland, pp 553–593Google Scholar
  91. 91.
    Thomas MA, Ibels LS (1985) Rhabdomyolysis and acute renal failure. Aust N Z J Med 15(5):623–8Google Scholar
  92. 92.
    Tonin P, Lewis P, Servidei S, DiMauro S (1990) Metabolic causes of myoglobinuria. Ann Neurol 27(2):181–5Google Scholar
  93. 93.
    Tsurui S, Sugie H, Ito M, Igarashi Y (1995) Clinical and biochemical analysis of 27 patients with myoglobinuria of unknown causes. Rinsho Shinkeigaku 35(1):24–8Google Scholar
  94. 94.
    Urbano-Marquez A, Estruch R, Navarro-Lopez F, Grau JM, Mont L, Rubin E (1989) The effects of alcoholism on skeletal and cardiac muscle. N Engl J Med 16;320(7):409–15Google Scholar
  95. 95.
    Verrips A, Poels PJE, Gabreëls FJM (2002) Rhabdomyolysis and Myoglobinuria. In: Katitji B, Kaminski H, Preston DC, Ruff RL, Shapiro BE (Hrsg) Neuromuscular disorders in clinical practice. Butterworth-Heinemann, Boston, pp 1319–1333Google Scholar
  96. 96.
    Verzijl HT, van Engelen BG, Luyten JA et al. (1998) Genetic characteristics of myoadenylate deaminase deficiency. Ann Neurol 44(1):140–3Google Scholar
  97. 97.
    Visweswaran P, Guntupalli J (1999) Rhabdomyolysis. Crit Care Clin 15(2):415–28Google Scholar
  98. 98.
    Vladutiu GD, Hogan K, Saponara I, Tassini L, Conroy J (1993) Carnitine palmitoyl transferase deficiency in malignant hyperthermia. Muscle Nerve 16(5):485–91Google Scholar
  99. 99.
    Warren JD, Blumbergs PC, Thompson PD (2002) Rhabdomyolysis: a review. Muscle Nerve 25(3):332–47Google Scholar
  100. 100.
    Wieser T, Deschauer M, Olek K, Hermann TH, Zierz S (2003) Carnitine palmitoyltransferase II deficiency – molecular and biochemical analysis of 32 patients. Neurology 60(8):1351–3Google Scholar
  101. 101.
    Zager RA (1996) Rhabdomyolysis and myohemoglobinuric acute renal failure. Kidney Int. 49(2):314–26Google Scholar
  102. 102.
    Zierz S, Engel AG (1985) Regulatory properties of a mutant carnitine palmitoyltransferase in human skeletal muscle. Eur J Biochem 15;149(1):207–14Google Scholar
  103. 103.
    Zierz S, Jerusalem F (1989) Mitochondrial myopathies and encephalomyelopathies. Nervenarzt 60(7):394–400Google Scholar
  104. 104.
    Zierz S (1994) Carnitine palmitoyltransferase deficiency. In: Engel AG, Franzini-Armstrong C (eds) Myology, Vol 2. Mc-Graw-Hill, New York, pp 1577–1586Google Scholar

Copyright information

© Springer-Verlag 2003

Authors and Affiliations

  1. 1.Neurologische KlinikMarienhospital Stuttgart
  2. 2.Neurologische Klinik und PoliklinikMartin-Luther-Universität Halle-Wittenberg
  3. 3.Neurologische KlinikMarienhospital StuttgartStuttgart

Personalised recommendations